Ukoniq™(umbralisib) – Voluntary withdrawal
April 15, 2022 - TG Therapeutics announced it has voluntarily withdrawn Ukoniq (umbralisib) from sale for the approved indications of treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen, and treatment of adult patients with follicular lymphoma (FL) who have received at least three prior systemic therapies.
Top